CDNA
CareDx
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CDNA
Caredx, Inc.
A leading precision medicine solutions company that focused on developing healthcare solutions for transplant patients and caregivers
Healthcare Equipment and Supplies
12/21/1998
07/17/2014
NASDAQ Stock Exchange
644
12-31
Common stock
8000 Marina Boulevard, Brisbane, California 94005
--
CareDx, Inc., was incorporated in Delaware on December 21, 1998. The company is a commercial stage company that develops decision markets and provides heart transplants to patients to help clinicians diagnose, monitor solutions and personalize treatments. CareDx's first commercialized test protocol, AlloMap Molecular Test Heart Transplant, or AlloMap Blood-Based Test, is used to monitor acute cellular rejection after heart transplantation.
Company Financials
EPS
CDNA has released its 2025 Q1 earnings. EPS was reported at 0.09, versus the expected 0.07, beating expectations. The chart below visualizes how CDNA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CDNA has released its 2024 Q4 earnings report, with revenue of 86.58M, reflecting a YoY change of 32.04%, and net profit of 78.01M, showing a YoY change of 166.06%. The Sankey diagram below clearly presents CDNA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
